Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats

Metabolic Brain Disease

Volumn 30, Issue 3, 2015, Pages 719-730

  Sharma, Ajaykumar N ^a,b   Pise, Ashish ^a   Sharma, Jay N ^c   Shukla, Praveen ^d  

^a STES's Smt Kashibai Navale College of Pharmacy   (India)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Ethanol dependence; GLP 1 receptor; Liraglutide; Tolerance

Indexed keywords

ALCOHOL; ANXIOLYTIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE;

AGONISTS; ANIMAL; ANXIETY; DOSE RESPONSE; DRUG TOLERANCE; MALE; PSYCHOLOGY; RAT; SUBSTANCE WITHDRAWAL SYNDROME; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ETHANOL; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIRAGLUTIDE; MALE; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84939950881     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9627-z     Document Type: Article

References (46)

1. Bhisikar SM, Kokare DM, Nakhate KT, Chopde CT, Subhedar NK (2009) Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors. Life Sci 85:765–772
2. Cajochen C, Kräuchi K, Wirz-Justice A (2003) Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15:432–437
3. Chen S, Liu AR, An FM, Yao WB, Gao XD (2012) Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr) 34:1211–1224
4. Cunningham CL, Fidler TL, Hill KG (2000) Animal models of alcohol’s motivational effects. Alcohol Res Health 24:85–92
5. de la Monte SM, Tong M, Cohen AC, Sheedy D, Harper C, Wands JR (2008) Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res 32:1630–1644
6. Dixit TS, Sharma AN, Lucot JB, Elased KM (2013) Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav 114–115:38–41
7. Egecioglu E, Engel JA, Jerlhag E (2013a) The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 8:e69010
8. Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E (2013b) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259–1270
9. Ernst A, Sharma AN, Elased KM, Guest P, Rahmoune H, Bahn S (2013) Diabetic db/db mice exhibit central and peripheral molecular alterations as observed in neurological disorders. Transl Psychiatry 28:e263
10. Gough SC (2012) Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab 14(Suppl 2):33–40
11. Grant P, Lipscomb D, Quin J (2011) Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complicat 25:244–246
12. Grosshans M, Mutschler J, Luderer M, Mann K, Kiefer F (2014) Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients. Clin Neuropharmacol 37:6–8
13. Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, Heilig JS (2013) Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J Comp Neurol 521:2235–2261
14. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT (2005) Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology (Berlin) 180:267–278
15. Hunter K, Holscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33
16. Jarosz J, Miernik K, Wachal M, Walczak J, Krumpl G (2013) Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse 39:144–160
17. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB (2012) Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes Metab 14:531–538
18. Kemp DM, Ubeda M, Habener JF (2002) Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: Potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 191:157–166
19. Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149–171
20. Kushner MG, Thuras P, Abrams K, Brekke M, Stritar L (2001) Anxiety mediates the association between anxiety sensitivity and coping-related drinking motives in alcoholism treatment patients. Addict Behav 26:869–885
21. Lader MH (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9(Suppl 6):S399–S405
22. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA (2014) Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry. doi:10.1016/j.biopsych.2014.03.019
23. Mann K, Kiefer F, Spanagel R, Littleton J (2008) Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32:1105–1110
24. Nutt D, Adinoff B, Linnoila M (1989) Benzodiazepines in the treatment of alcoholism. Recent Dev Alcohol 7:283–313
25. Roelofs SM (1985) Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. Alcohol 2:501–505
26. Rojdmark S, Calissendorff J, Brismar K (2001) Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals. Clin Endocrinol (Oxford) 55:639–647, 1401
27. Samson HH, Harris RA (1992) Neurobiology of alcohol abuse. Trends Pharmacol Sci 13:206–211
28. Sharma AN, Chopde CT, Hirani K, Kokare DM, Ugale RR (2007) Chronic progesterone treatment augments while dehydroepiandrosterone sulphate prevents tolerance to ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharmacol 567:211–222
29. Sharma AN, Elased KM, Garrett TL, Lucot JB (2010) Neurobehavioral deficits in db/db diabetic mice. Physiol Behav 101:381–388
30. Sharma AN, Elased KM, Lucot JB (2012) Rosiglitazone reverses depression but not psychosis-like behavior in db/db diabetic mice. J Psychopharmacol 26:724–732
31. Sharma AN, Pise A, Sharma JN, Shukla P (2014a) Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats. Metab Brain Dis. doi:10.1007/s11011-014-9603-7
32. Sharma AN, Bauer E, Sanches M, Galvez JF, Zunta-Soares GB, Quevedo J, Kapczinski F, Soares JC (2014b) Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry 54:289–298
33. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F, Jaschke A, Schurmann A, Prevot V, Shao R, Jansson JO, Skibicka KP (2013) Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A 110:16199–16204
34. Shukla P, O’Rourke S (2009) Melatonin inhibits NO-induced cGMP accumulation in porcine coronary arteries. FASEB J 23:933, 12
35. Shukla P, O’Rourke S (2011) Down regulation of protein kinase G1α/β (PKG1α/β) inhibits melatonin-induced phosphorylation of phosphodiesterase 5 (PDE5) in coronary arteries. FASEB J 25:808.9
36. Shukla P, Yao F, Pawel A, Sun BC, O’Rourke S (2011) Melatonin inhibits large conductance, calcium-activated k channel activity in porcine coronary artery smooth muscle cells by activating MT2-receptors. Circulation 124:A16932
37. Shukla P, Sun C, O’Rourke ST (2012a) Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries. Am J Physiol Heart Circ Physiol 303:H1418–H1425
38. Shukla P, Lemley CO, O’Rourke S, Meyer AM, Vonnahme K (2012b) Differential vascular reactivity of fetal and maternal placental arteries from melatonin treated nutrient-restricted sheep to endothelium-dependent and independent vasodilators. FASEB J 26:712–715
39. Shukla P, Sun C, O’Rourke S (2012c) Melatonin inhibits NO-induced activation of BKCa channels and relaxation of coronary arteries by increasing PKG1-dependent phosphorylation of PDE5. Circulation 126:A16569
40. Shukla P, Sun C, O’Rourke S (2012d) Melatonin inhibits NO-dependent activation of large conductance, calcium-activated K channels (BKCa) in porcine coronary artery smooth muscle cells. FASEB J 26:842.1
41. Shukla P, Lemley CO, Dubey N, Meyer AM, O’Rourke ST, Vonnahme KA (2014) Effect of maternal nutrient restriction and melatonin supplementation from mid to late gestation on vascular reactivity of maternal and fetal placental arteries. Placenta 35:461–466
42. Sinclair JD, Lindros KO (1981) Suppression of alcohol drinking with brain aldehyde dehydrogenase inhibition. Pharmacol Biochem Behav 14:377–383
43. Tunstall RR, Shukla P, Grazul-Bilska A, Sun C, O’Rourke ST (2011) MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries. J Pharmacol Exp Ther 336:127–133
44. Ugale RR, Sharma AN, Hirani K, Kokare DM, Chopde CT (2007) Neurosteroidal role in anxiolytic action of nonbenzodiazepine etifoxine in rats. Brain Res 1184:193–201
45. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA (2002) Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410–1415
46. Vonnahme KA, Lemley CO, Shukla P, O’Rourke ST (2013) 2011 and 2012 Early Careers Achievement Awards: Placental programming: how the maternal environment can impact placental function. J Anim Sci 91:2467–2480